Remternetug

Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ. Remternetug results in rapid and robust amyloid plaque reduction. Remternetug can be used for Alzheimer's disease research[1][2].

Product Specifications

CAS Number

[2571940-41-3]

Product Name Alternative

LY3372993

UNSPSC

12352203

Target

Amyloid-β

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/remternetug.html

Purity

99.00

Solubility

10 mM in DMSO

Smiles

[Remternetug]

Molecular Weight

(144.916 kDa)

References & Citations

[1]Li-Kai Huang, et al. Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update. J Biomed Sci. 2023 Oct 2;30 (1) :83.|[2]Meglio M. Alzheimer Disease Pipeline Update: Inside Look at Promising Agents. Neurology Live, 2023: NA-NA.